amiodarone
DISEASE INTERVENTION COMPARISON RESULTS
Circulation. 2002 Jul 16;106(3):331-6 Randomized Controlled Trial
IN atrial fibrillation, persistent The Use of
angiotensin II receptor blockers (irbesartan), added to amiodarone
As Treatment, Chronic
Is better Than
amiodarone alone
To reduce, at 9 months, recurrence of AF: 20% ibersartan plus VS 44% amiodarone alone
J Card Fail. 2007 Jun;13(5):340-5. Controlled Trial (non-randomized)
IN antiarrthythmic drugs, amiodarone, adverse effects, mortality, atrial fibrillation, heart failure The Use of
amiodarone
As Treatment, Chronic
Is worse Than
no amiodarone
To mortality: risk of death due to circulatory failure with amiodarone: HR 1.5
S Afr Med J. 2005 Mar;95(3):180-3 Cohorts
IN antiarrthythmic drugs, amiodarone, adverse effects, thyroid The Use of
amiodarone
As Treatment, Chronic
Is bad Than
no treatment
To develop thyroid dysfunction (either hyper or hypothyroidism): 27.6% of treated patients after a mean of 943 days of treatment VS mean 547 days in euthyroid patients.
Am J Med. 2007 Oct;120(10):880-5 Randomized Controlled Trial
IN antiarrthythmic drugs, amiodarone, adverse effects, thyroid The Use of
amiodarone
As Treatment, Chronic
Is worse Than
placebo
To alter thyroid function: hypothyroidism developed in 30.8%, hyperthyroidism in 5.3%
JAMA. 2007 Sep 19;298(11):1312-22 Systematic Review
IN antiarrthythmic drugs, amiodarone, clinical indications, adverse effects The Use of
amiodarone
As Treatment, Acute
Is better Than
placebo or no treatment or other antiarrhythmics
To treat atrial fibrillation with left ventricular dysfunction, sustained ventricular arrhythmias, patients about to undergo cardiac surgery, and implantable cardioverter-defibrillators and symptomatic shocks.
Mayo Clin Proc. 2009 Mar;84(3):234-42 Meta-Analysis
IN antiarrthythmic drugs, amiodarone, clinical use, adverse effects, atrial fibrillation, persistent, rhythm control strategy The Use of
amiodarone, low dose, 100 to 200 mg/d
As Treatment, Chronic
Is better Than
placebo
To restore and keep sinus rhythm (21.3% amiodarone vs 9.2% placebo at 1 year) but increase withdrawals by side effects (10.7% per year amiodarone vs 1.9% placebo)
Clin Pharmacol Ther. 2000 Jun;67(6):642-52 Cohorts
IN antiarrthythmic drugs, amiodarone, pharmacokinetics The Use of
amiodarone pharmacokinetics
As Dosage Scheme
Is useful Than
-
To help guide chronic treatment.
J Pharmacokinet Biopharm. 1999 Aug;27(4):383-96 Review (Narrative)
IN antiarrthythmic drugs, amiodarone, pharmacokinetics The Use of
new hypothesis on amiodarone pharmacokinetics
As Treatment, Acute
Is useful Than
-
To help develop new therapeutic and dosage schemes
Am J Cardiol. 1994 Oct 1;74(7):681-6 Randomized Controlled Trial
IN antiarrthythmic drugs, amiodarone, pharmacokinetics, very low dose maintenance The Use of
amiodarone, very low dose, 100 mg/d
As Treatment, Chronic
Is better Than
amiodarone 50 mg/d or placebo
To reduce, at 12 weeks, ventricular arrhythmias (total suppression in 10/14 patients amiodarone 100mg/d VS 4/15 placebo
Ann Intern Med 1999 Apr 20;130(8):625-36 Cost-Effectiveness
IN atrial fibrillation The Use of
cardioversion alone followed by repeated cardioversion plus amiodarone therapy on relapse
As Treatment, Chronic
Is better Than
cardioversion alone followed by warfarin therapy on relapse
To gain expected costs per quality-adjusted life-year (QALY). In the lowest-risk of stroke cohort, cardioversion alone followed by aspirin therapy on relapse was optimal.
Arch Intern Med 1998 Aug 10-24;158(15):1669-77 Cost-Effectiveness
IN atrial fibrillation The Use of
cardioversion followed by the use of aspirin alone or with amiodarone
As Treatment, Chronic
Is better Than
cardioversion followed by the use of amiodarone and warfarin
To gain expected costs per quality-adjusted life-year (QALY), but marginally, and cardioversion followed by amiodarone and warfarin resulted in the greatest gain in QALYs
Eur Heart J. 2006 Aug;27(15):1841-6 Randomized Controlled Trial
IN atrial fibrillation, paroxysmal The Use of
angiotensin converting enzyme (ACE) inhibitors (perindopril) or angiotensin II receptor blockers (losartan), added to amiodarone
As Treatment, Chronic
Is better Than
amiodarone alone
To reduce, at 2 years, recurrence of AF: 19% with sartan VS 24% with ACE inhibitor VS 41% amiodarone alone.
JAMA. 2008 Oct 15;300(15):1784-92 Randomized Controlled Trial
IN atrial fibrillation, paroxysmal, recurrent The Use of
continuous amiodarone, after electrical cardioversion
As Treatment, Chronic
Is better Than
amiodarone, episodic treatment, 1 month peri-electrical cardioversion
To reduce major events (either drug- or heart-related): 35% episodic VS 33% continouous amiodarone. All-cause mortality and cardiovascular hospitalizations were higher among those receiving episodic treatment (53% VS 34% continuous)
Eur Heart J. 2003 Dec;24(23):2090-8 Randomized Controlled Trial
IN atrial fibrillation, persistent The Use of
angiotensin converting enzyme (ACE) inhibitors, enalapril, added to amiodarone
As Treatment, Chronic
Is better Than
amiodarone alone
To increase number of patients in SR at at 8 months: 84.3% enalapril VS 61.3% amiodarone alone
Ann Intern Med. 1994 Mar 15;120(6):449-57 Decision Model
IN atrial fibrillation, persistent The Use of
rhythm control using amiodarone
As Treatment, Chronic
Is better Than
some other strategies: no treatment, warfarin alone, rhythm control using quinidine
To gain more quality-adjusted life-years: amiodarone obtained the best value (4.75 years), followed by warfarin (4.72 years), quinidine (4.68 years), and no treatment (4.55 years).
Pharmacotherapy. 2007 Mar;27(3):360-8 Meta-Analysis
IN atrial fibrillation, postoperative, cardiac surgery The Use of
amiodarone, total doses > 3 grs, starting before or after surgery
As Prevention, Primary
Is better Than
placebo
To reduce the incidence of post-operative atrial fibrillation (OR 0.50)
Ann Intern Med. 2005 Sep 6;143(5):327-36 Meta-Analysis
IN atrial fibrillation, postoperative, cardiac surgery The Use of
antiarrhythmics, amiodarone
As Prevention, Primary
Is better Than
placebo
To decrease the incidence of atrial fibrillation or flutter (RR 0.64), ventricular arrhythmia (RR 0.42) and stroke (RR 0.39)
Eur Heart J. 2006 Jul;27(13):1584-91. Epub 2006 Jun 7 Randomized Controlled Trial
IN atrial fibrillation, postoperative, cardiac surgery The Use of
prophylaxis using antiarrhythmics, amiodarone, 600 mg oral single dose per day from Day-1 to Day7 plus IV perfusion during surgery
As Prevention, Primary
Is better Than
placebo
To reduce the incidence of post-operative AF: 34% with amiodarone VS 85% placebo. Also reduced hospitalization length of stay. Blood concentrations of amiodarone sig. differed between patients.
Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003611 Systematic Review, Cochrane Review
IN atrial fibrillation, postoperative, cardiac surgery The Use of
several antiarrhythmics (amiodarone, sotalol, beta-blockers) and pacing
As Prevention, Primary
Is better Than
placebo
To reduce the incidence of atrial fibrillation (OR between 0.26 and 0.49) and possibly (non significant) reduces stroke and lenght of stay
Zhonghua Yi Xue Za Zhi. 2006 Jan 10;86(2):121-3 Randomized Controlled Trial
IN atrial fibrillation, StudyID: Niu 2006 The Use of
amiodarone
As Treatment, Chronic
Is better Than
sotalol
To reduce, at 1 year, AF recurrence, with similar number of adverse events
Am Heart J. 2002 Oct;144(4):597-607 Randomized Controlled Trial
IN Study ID: AF-CHF 2008 (subordinated publication), atrial fibrillation, rate control strategy, heart failure, chronic, systolic The Use of
rhythm control: electrical cardioversion combined with antiarrhythmic drugs (amiodarone or other class III agents)
As Treatment, Chronic
Is undefined Than
rate control
To primary end point : cardiovascular mortality (protocol for a RCT)
J Am Coll Cardiol. 2003 Jul 2;42(1):20-9 Randomized Controlled Trial
IN StudyID: AFFIRM Substudy 2003, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is better Than
sotalol, or a class I drug
To composite outcome (patients alive, in sinus rhythm, with no additional cardioversions and still taking the assigned drug) at 12 months: 60% amiodarone, 38% sotalol, 23% class I agents. Adverse effects were common.
Rev Esp Cardiol. 1978;31(1 Pt 2):185-91 Randomized Controlled Trial
IN StudyID: Aros 1978, atrial fibrillation The Use of
quinidine plus amiodarone
As Treatment, Chronic
Is better Than
quinidine alone
To not available
Arch Intern Med. 1987 Aug;147(8):1401-4 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Blevins 1987, atrial fibrillation, persistent, rejected The Use of
Amiodarone
As Treatment, Acute, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at 16 Months
Acta Med Scand. 1984;216(5):517-24 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Blomstrom 1984, atrial fibrillation, rejected The Use of
amiodarone
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at ? Months
Am J Cardiol. 1987 Sep 1;60(7):572-5 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Brodsky 1987, atrial fibrillation, persistent, rejected The Use of
Amiodarone
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at 12 Months
Eur Heart J. 2004 Jan;25(2):144-50 Randomized Controlled Trial
IN StudyID: Channer 2004, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 12 months
J Am Coll Cardiol. 2003 Jan 15;41(2):255-62 Meta-Analysis
IN StudyID: Chevalier 2003, atrial fibrillation The Use of
amiodarone
As Treatment, Acute
Is better Than
placebo
To converting AF to sinus rhythm. No difference in trials comparing againts class Ic drugs
Circulation. 1998 Dec 8;98(23):2574-9 Randomized Controlled Trial, Multicenter Trial
IN StudyID: CHF-STAT 1998, atrial fibrillation, heart failure The Use of
amiodarone
As Treatment, Chronic
Is better Than
placebo
To mortality, AF recurrence - at 12 months
Am J Cardiol. 1995 Jul 1;76(1):47-50 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Chun 1995, atrial fibrillation, paroxysmal, persistent The Use of
amiodarone
As Treatment, Chronic
Is good Than
no control group
To mortality, adverse effects, proarrhythmia, AF recurrence - at 12 months
Am J Cardiol. 1997 Aug 15;80(4):464-8 Randomized Controlled Trial
IN StudyID: CTAF 2000 (subordinated publication), atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is better Than
sotalol, propafenone
To AF recurrence, adverse effects, cost, quality of life - at 12 months
Eur Heart J. 2002 Jul;23(13):1050-6 Randomized Controlled Trial, Multicenter Trial
IN StudyID: CTAF 2000 (subordinated publication), atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is better Than
sotalol, propafenone
To hospital and physician costs per patient - at 12 months
Am Heart J. 2002 Jun;143(6):984-90 Randomized Controlled Trial
IN StudyID: CTAF 2000 (subordinated publication), atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is better Than
sotalol, propafenone
To improve quality of life - at 1 year
N Engl J Med. 2000 Mar 30;342(13):913-20 Randomized Controlled Trial
IN StudyID: CTAF 2000, atrial fibrillation The Use of
amiodarone, low dose
As Treatment, Chronic
Is better Than
sotalol, propafenone
To AF recurrence, adverse effects - at 12 months
Rev Esp Cardiol. 1998;51(Suppl 5):84 Randomized Controlled Trial
IN StudyID: Fernandez 1998, atrial fibrillation, paroxysmal The Use of
amiodarone, flecainide
As Treatment, Acute
Is - Than
propafenone
To acute revers atrial fibrillation to sinus rhythm
J Cardiovasc Pharmacol Ther. 2003 Sep;8(3):179-86 Clinical Trial (non-controlled, non-randomized)
IN StudyID: GEFACA 2001 (subordinated publication), atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is - Than
no comparison
To AF recurrence, adverse effects - at > 12 months
J Cardiovasc Pharmacol Ther. 2001 Oct;6(4):341-50 Randomized Controlled Trial, Multicenter Trial
IN StudyID: GEFACA 2001, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at average 9 months
Am J Cardiol. 1986 Jan 1;57(1):124-7 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Gold 1986, atrial fibrillation, persistent, rejected The Use of
Amiodarone
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at ? Months
JAMA. 1992 Jun 24; 267(24): 3289-93 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Gosselink 1992, atrial fibrillation, rejected The Use of
amiodarone
As Treatment, Chronic
Is useful Than
no controls
To AF recurrence, adverse effects - at 3 years
Am Heart J. 1983 Oct;106(4 Pt 2):870-6 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Graboys 1983, atrial fibrillation, paroxysmal, rejected The Use of
amiodarone
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at 27,3 Months
J Am Coll Cardiol. 1985 Dec;6(6):1402-7 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Horowitz 1985, atrial fibrillation, persistent, rejected The Use of
amiodarone
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects - at 15 months
Chin Med J (Engl). 2006 Dec 20;119(24):2030-5 Randomized Controlled Trial
IN StudyID: Jong 2006, antiarrthythmic drugs, amiodarone, pharmacokinetics, very low dose maintenance The Use of
amiodarone, very low dose, 100 mg/d
As Treatment, Chronic
Is equal Than
amiodarone, usual low dose, 200 mg/d
To maintain sinus rhythm at 5 year, after cardioversion of atrial fibrillation: 42% with 200mg/d VS 36% with 100 mg/d. Less adverse effects in the lower dose.
Z Kardiol. 1994;83(5):109-116 Randomized Controlled Trial
IN StudyID: Kalusche 1994, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is equal Than
quinidine + verapamil
To
Am J Cardiol. 2004 Sep 1;94(5):659-62 Randomized Controlled Trial
IN StudyID: Kanoupakis 2004, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, adverse effects - at 4 weeks
Chest. 2004 Feb;125(2):377-83 Randomized Controlled Trial
IN StudyID: Kochiadakis-AmPro 2004, atrial fibrillation The Use of
amiodarone, propafenone
As Treatment, Chronic
Is good Than
0
To AF recurrence, adverse effects - at 10 months
Am J Cardiol. 1998 Apr 15;81(8):995-8 Randomized Controlled Trial
IN StudyID: Kochiadakis-AmSot 2000 (subordinated publication DVD), atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is better Than
sotalol
To AF recurrence, adverse effects - at 12 months
Pacing Clin Electrophysiol. 2000 Nov;23(11 Pt 2):1883-7 Randomized Controlled Trial
IN StudyID: Kochiadakis-AmSot 2000 (subordinated publication), atrial fibrillation The Use of
amiodarone, propafenone
As Treatment, Chronic
Is better Than
sotalol
To AF recurrence, adverse effects - at 6 to 16 months
Heart 2000 Sep;84(3):251-7 Randomized Controlled Trial
IN StudyID: Kochiadakis-AmSot 2000, atrial fibrillation The Use of
amiodarone, sotalol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 6 to 16 months
Arch Intern Med. 2003 Apr 14;163(7):777-85 Meta-Analysis
IN StudyID: Letelier 2003, atrial fibrillation The Use of
amiodarone
As Treatment, Acute
Is better Than
placebo
To converting AF to sinus rhythm
Cardiovasc Drugs Ther. 2003 Jan;17(1):31-39 Randomized Controlled Trial
IN StudyID: Manios 2003, atrial fibrillation, rejected The Use of
amiodarone
As Treatment, Chronic
Is better Than
diltiazem, no treatment
To AF recurrence - at 6 weeks
British Journal of Clinical Practice. Supplement. 1986 Apr;44:52-60 Controlled Trial (non-randomized)
IN StudyID: Martin 1986, atrial fibrillation, paroxysmal The Use of
amiodarone
As Treatment, Chronic
Is not available Than
disopyramide
To not available
New Trends in Arrhytmias. 1991;7(4):693-698 Cross-Over
IN StudyID: Massacci 1991, atrial fibrillation, paroxysmal, recurrent The Use of
amiodarone
As Treatment, Chronic
Is equal Than
flecainide
To AF recurrence, adverse effects - at 4 weeks
Ter Arkh. 1990; 62(9): 47-51 not available
IN StudyID: Nedostup 1990, atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is - Than
quinidine
To not available
Clin Cardiol. 1997 Apr;20(4):337-40 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Opolski 1997, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, adverse effects - at 12 months
Eur Heart J. 2003 Aug;24(15):1430-6 Randomized Controlled Trial
IN StudyID: PIAF 2000 (subordinated publication), atrial fibrillation, rate control strategy, functional status The Use of
rhythm control strategy (amiodarone)
As Treatment, Chronic
Is equal Than
rate control strategy (verapamil and anticoagulation)
To impact on quality of life - at 1 year
Lancet. 2000 Nov 25;356(9244):1789-94 Randomized Controlled Trial
IN StudyID: PIAF 2000, atrial fibrillation, rate control strategy The Use of
rhythm control strategy (amiodarone)
As Treatment, Acute
Is equal Than
rate control strategy (verapamil and anticoagulation)
To improvement in symptoms related to atrial fibrillation. Exercise tolerance is better with rhythm control, although hospital admission is more frequent. Only 23% patients in amiodarone were in sinus rhythm at 1 year.
Am J Cardiol. 2003 Aug 15;92(4):468-72 Randomized Controlled Trial
IN StudyID: Safe-T 2005 (subordinated publication), atrial fibrillation The Use of
amiodarone, sotalol
As Treatment, Chronic
Is - Than
placebo
To AF recurrence, a number of parameters as secondary end points - at 12 to 54 months
N Engl J Med. 2005 May 5;352(18):1861-72 Randomized Controlled Trial
IN StudyID: Safe-T 2005, atrial fibrillation, persistent The Use of
amiodarone, sotalol
As Treatment, Chronic
Is better Than
placebo
To mortality, stroke, proarrhythmia, AF recurrence - at 12 months
Prog Cardiovasc Dis. 2001 Sep-Oct;44(2):121-52 Meta-Analysis
IN StudyID: Slavik 2001, atrial fibrillation The Use of
IV procainamide, oral quinidine, oral flecainide, oral propafenone, IV or hight-dose oral amiodarone, IV ibutilide
As Treatment, Acute
Is better Than
placebo
To converting AF to sinus rhythm
Br J Clin Pract Suppl. 1986 Apr;44:42-8 Cross-Over
IN StudyID: Tonet 1986, atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is unknown Than
quinidine
To unknown
Eur Heart J. 2003 Aug;24(15):1425-9 Randomized Controlled Trial, Multicenter Trial
IN StudyID: VERARAF 2003, atrial fibrillation, persistent The Use of
amiodarone, flecainide, verapamil
As Treatment, Chronic
Is equal Than
flecainide, verapamil addition to any of both
To AF recurrence - at 3? Month
Clin Ter. 1992 Jan; 140(1 Pt 2): 35-9 Randomized Controlled Trial
IN StudyID: Villani 1992, atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is better Than
disopyramide
To AF recurrence, adverse effects - at 12 months
Acta Cardiologica. 1981;36(6):431-44 Clinical Trial
IN StudyID: Vitolo 1981, atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is not available Than
quinidine
To not available
J Am Coll Cardiol. 1997 Sep;30(3):791-8 Meta-Analysis
IN StudyID: Vorperian 1997, antiarrhythmic drugs, amiodarone, adverse effects The Use of
amiodarone, low dose maintenace
As Treatment, Chronic
Is worse Than
placebo
To produce at 12 months more side effects: thyroid OR 4,2 ; thyroid OR 4,2 ; ocular OR 3,4 ; skin OR 2,5 ; bradycardic OR 2,2 ; neurologic OR 2,0. Treatment withdrawal: 23% in amiodarone, 15% placebo
Arch Intern Med 1995 Sep 25;155(17):1885-91 Meta-Analysis
IN StudyID: Zarembski, atrial fibrillation, existing meta-analysis The Use of
amiodarone
As Treatment, Chronic
Is equal Than
flecainide
To maintenance of sinus rhythm.
Z Kardiol. 1994;83(Suppl 5):101-8 Randomized Controlled Trial
IN StudyID: Zehender 1992 (subordinated publication), atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Acute
Is equal Than
quinidine + verapamil
To acute conversion of chronic AF
J Am Coll Cardiol. 1992 Apr;19(5):1054-9 Randomized Controlled Trial
IN StudyID: Zehender 1992, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is equal Than
quinidine + verapamil
To acute conversion of chronic AF